Article

Laser yields safe, predictable correction for astigmatism

An ongoing multinational study is evaluating LASIK for myopia and myopic astigmatism performed with a new-generation excimer laser (Schwind Amaris, Schwind eye-tech-solutions) using its aspheric, aberration-free ablation profile.

Key Points

Dr. Barraquer, a study investigator in private practice in Bogota, Colombia, reported that 364 patients have been enrolled in the study, and all were seen for follow-up at 3 months. Preoperatively, they had a mean spherical equivalent (SE) of –3.50 D with a range between –0.5 and –8.5 D. The patients had up to –9 D of sphere and up to –7 D of astigmatism.

At 3 months post LASIK, mean SE was –0.17 ± 0.24 D (range, –1 to +0.62 D). Uncorrected visual acuity was 20/16 or better in 55% of eyes, 20/20 or better in 95% of eyes, and 20/25 or better in 100%. Predictability was excellent, with refraction within 0.25 D of intended in 75% of eyes and ±0.50 D in 92%. All eyes were corrected within 1 D of attempted, and in an analysis of defocus, 89% of eyes had an outcome of 0 D.

Results of a wavefront analysis showed that, true to its name, the aspheric aberration-free treatment corrected the lower aberrations but left the preoperative higher-order aberrations (HOAs) essentially unchanged.

"The [new excimer laser] is demonstrating encouraging results in this preliminary analysis," Dr. Barraquer said. "Now we need long-term studies and to evaluate outcomes from treatments performed with the customized ablation profiles of this new laser platform."

The patients enrolled in the study had a mean age of 28 years. All flaps were created using a proprietary microkeratome (Carriazo-Pendular, Schwind eye-tech-solutions).

Dr. Barraquer said that refractive stability appeared promising, but with only 3 months of follow-up, it was too early to review that issue.

Correction of astigmatism was investigated with vector analysis. Dr. Barraquer noted the results were good overall, although there were a few outliers.

About the laser system

The new excimer laser operates with a repetition rate of 500 Hz and has automatic fluence adjustment with two fluence levels, a high fluence level that enables rapid treatment and a low fluence level used for fine correction to improve the resolution. The result is shortened treatment time without jeopardizing treatment precision and safety.

The device is a flying spot laser featuring a super-Gaussian beam profile with a very small beam size of 0.54 mm to deliver accurate ablations and a smooth surface. It also has an advanced eye tracker that works at 1,050 Hz and compensates for eye movements in five dimensions: horizontal and vertical displacement, horizontal and vertical rotation, and cyclotorsion.

"The tracking system is based on pupil position and the limbus, has a rapid response time of less than 3 milliseconds, and offers static and dynamic cyclotorsional control along with pupil centroid shift control," Dr. Barraquer said. "The [excimer laser] platform also has an option for integrated online, high-resolution pachymetry."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.